GLP1R and chronic kidney disease: In terms of comorbidities/cardiovascular events (both prior to enrollment and during follow-up), CAD (OR 1.29, 95% CI 1.08–1.54) was associated with greater use of SGLT2i or GLP-1 RA while PAD and CKD were associated with lower use (PAD: OR 0.73, 95% CI 0.54–1.00; CKD: OR 0.73, 95% CI 0.58–0.94).